Form D · Biotechnology
Nu-Med Plus, Inc.
Salt Lake City, UT · CIK 0001543637
Offering snapshot reported Dec 7, 2018 · SEC filing
- Reported sold
- $35K Offering amount: $600K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Oct 18, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 7, 2018 | Initial | $35,000 | No comparison | 2 | SEC filing |
| Sep 20, 2017 | Amendment | $660,405 | $360,405vs Feb 2, 2017 | 4 | SEC filing |
| Sep 14, 2017 | Initial | $45,000 | No comparison | 1 | SEC filing |
| Feb 2, 2017 | Initial | $300,000 | No comparison | 1 | SEC filing |
| Aug 19, 2015 | Initial | $2,500 | No comparison | 1 | SEC filing |
| Apr 21, 2015 | Initial | $30,000 | No comparison | 1 | SEC filing |
| Sep 2, 2014 | Amendment | $164,000 | $30,000vs May 28, 2014 | 3 | SEC filing |
| May 28, 2014 | Amendment | $134,000 | $12,500vs May 1, 2014 | 2 | SEC filing |
| May 1, 2014 | Amendment | $130,000 | $80,000vs Oct 30, 2013 | 1 | SEC filing |
| May 1, 2014 | Initial | $121,500 | No comparison | 2 | SEC filing |
| Oct 30, 2013 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Mar 13, 2012 | Initial | $87,653 | No comparison | 55 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-327428
Source: Form D, filed Dec 7, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brett J. Earl, Md | Director, Executive |
| Keith Merrell | Executive |
| William Grant Moon | Director, Executive |
| Craig W. Morrison | Director, Executive |
| Jeffrey L. Robins | Director, Executive |
| Tom Tait | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
455 East 500 South, Suite #203
Salt Lake City, UT, 84111
Salt Lake City, UT, 84111